LLC1 (LL-2) Cells

LLC1 (LL-2) cells are a murine cell line derived from the Lewis Lung Carcinoma (LLC), a tumor model extensively used for cancer research. These cells were originally isolated and adapted to in vitro culture from the Lewis Lung Carcinoma in C57BL/6 mice. LLC1 (LL-2) cells have a doubling time of 21 hours and retain high tumorigenic potential, forming primary tumors and lung metastases in syngeneic C57BL/6 mice that are histologically similar to the original tumor.
LLC1 (LL-2) cells have proven valuable for various experimental applications, including studies on cancer metastasis, tumor-host interactions, and drug sensitivity testing. Notably, while these cells show significant in vitro sensitivity to various chemotherapeutic agents, such as cisplatin and methotrexate, their in vivo response can differ, highlighting the complexity of translating in vitro findings to in vivo contexts. The ability of LLC1 (LL-2) cells to form discrete colonies on plastic substrates also makes them suitable for use in focus assays to evaluate drug-induced cytotoxicity, making them an important tool in the evaluation of new cancer therapies.
LLC1 (LL-2) cells exhibit several features typical of aggressive lung carcinoma, including rapid proliferation, high metastatic potential, and resistance to certain chemotherapeutic agents. These cells provide a relevant model for understanding the molecular and genetic alterations associated with lung cancer progression. Studies utilizing LLC1 (LL-2) have contributed to the identification of key signaling pathways and genetic mutations involved in tumor development and metastasis. Moreover, this cell line has been instrumental in evaluating novel therapeutic strategies aimed at inhibiting tumor growth and spread, thereby advancing the field of oncology research.